Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2022-03-07 02:51:58 UTC |
---|
HMDB ID | HMDB0015391 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Decitabine |
---|
Description | Decitabine, also known as azadc or dacogen, belongs to the class of organic compounds known as triazinones. Triazinones are compounds containing a triazine ring which bears a ketone group a carbon atom. Decitabine is a drug which is used for treatment of patients with myelodysplastic syndromes (mds) including previously treated and untreated, de novo and secondary mds of all french-american-british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups (scores ≥0.5). Decitabine is an extremely weak basic (essentially neutral) compound (based on its pKa). It has been found that use of this DNA methyltranferase inhibitor prevents atherosclerosis lesion formation and reduces the production of inflammatory cytokines by macrophages. It functions in a similar manner to azacitidine, although decitabine can only be incorporated into DNA strands while azacitidine can be incorporated into both DNA and RNA chains. Therefore, the action of decitabine is division-dependent, meaning the cells have to divide in order for the pharmaceutical to act. Methylation of CpG islands upstream of tumor suppressor genes in order to silence them seems to be critical for these type of cancers. It incorporates into DNA strands upon replication, and then when DNA methyltransferases (DNMTs) such as DNMT1, are engaged to bind the DNA and to replicate the methylation to the daughter strand, DNMTs are bound to decitabine irreversibly and cannot disengage. This upregulates DNA methyltransferase expression, which leads to genome-wide DNA methylation alterations and global gene expression changes. Decitabine is used to treat myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups. In cancer cells, and more specifically in haematological malignancies, it seems that DNA hypermethylation is really critical for their development. It is a drug for the treatment of myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML). |
---|
Structure | NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1 InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1 |
---|
Synonyms | Value | Source |
---|
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one | ChEBI | 5-Azadeoxycytidine | ChEBI | Dacogen | Kegg | 4-Amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one | Generator | 4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one | Generator | 5-Aza-2'-deoxycytidine | HMDB | Azadc | HMDB | Dezocitidine | HMDB | 5-Deoxyazacytidine | HMDB | Decitabine mesylate | HMDB | 2'-Deoxy-5-azacytidine | HMDB | AzadC compound | HMDB | 2' Deoxy 5 azacytidine | HMDB | 5 Aza 2' deoxycytidine | HMDB | 5 Azadeoxycytidine | HMDB | 5 Deoxyazacytidine | HMDB | 5-AzadC | HMDB | 5AzadC | HMDB | Compound, azadc | HMDB | Mesylate, decitabine | HMDB | Decitabine | ChEBI |
|
---|
Chemical Formula | C8H12N4O4 |
---|
Average Molecular Weight | 228.2053 |
---|
Monoisotopic Molecular Weight | 228.085854892 |
---|
IUPAC Name | 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one |
---|
Traditional Name | decitabine |
---|
CAS Registry Number | 2353-33-5 |
---|
SMILES | NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1 |
---|
InChI Identifier | InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1 |
---|
InChI Key | XAUDJQYHKZQPEU-KVQBGUIXSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as triazinones. Triazinones are compounds containing a triazine ring which bears a ketone group a carbon atom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Triazines |
---|
Sub Class | Triazinones |
---|
Direct Parent | Triazinones |
---|
Alternative Parents | |
---|
Substituents | - Amino-1,3,5-triazine
- Aminotriazine
- Triazinone
- 1,3,5-triazine
- Tetrahydrofuran
- Heteroaromatic compound
- Secondary alcohol
- Oxacycle
- Azacycle
- Organic oxide
- Organopnictogen compound
- Alcohol
- Primary amine
- Primary alcohol
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Amine
- Hydrocarbon derivative
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 5.5 g/L | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Decitabine,1TMS,isomer #1 | C[Si](C)(C)O[C@H]1C[C@H](N2C=NC(N)=NC2=O)O[C@@H]1CO | 2308.7 | Semi standard non polar | 33892256 | Decitabine,1TMS,isomer #2 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)C[C@@H]1O | 2294.9 | Semi standard non polar | 33892256 | Decitabine,1TMS,isomer #3 | C[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)C=N1 | 2365.9 | Semi standard non polar | 33892256 | Decitabine,2TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)C[C@@H]1O[Si](C)(C)C | 2231.9 | Semi standard non polar | 33892256 | Decitabine,2TMS,isomer #2 | C[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O[Si](C)(C)C)[C@@H](CO)O2)C=N1 | 2321.5 | Semi standard non polar | 33892256 | Decitabine,2TMS,isomer #3 | C[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O)[C@@H](CO[Si](C)(C)C)O2)C=N1 | 2303.3 | Semi standard non polar | 33892256 | Decitabine,2TMS,isomer #4 | C[Si](C)(C)N(C1=NC(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)C=N1)[Si](C)(C)C | 2323.1 | Semi standard non polar | 33892256 | Decitabine,3TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O[Si](C)(C)C)[C@@H](CO[Si](C)(C)C)O2)C=N1 | 2291.2 | Semi standard non polar | 33892256 | Decitabine,3TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O[Si](C)(C)C)[C@@H](CO[Si](C)(C)C)O2)C=N1 | 2440.9 | Standard non polar | 33892256 | Decitabine,3TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O[Si](C)(C)C)[C@@H](CO[Si](C)(C)C)O2)C=N1 | 3383.8 | Standard polar | 33892256 | Decitabine,3TMS,isomer #2 | C[Si](C)(C)O[C@H]1C[C@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)O[C@@H]1CO | 2306.2 | Semi standard non polar | 33892256 | Decitabine,3TMS,isomer #2 | C[Si](C)(C)O[C@H]1C[C@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)O[C@@H]1CO | 2464.2 | Standard non polar | 33892256 | Decitabine,3TMS,isomer #2 | C[Si](C)(C)O[C@H]1C[C@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)O[C@@H]1CO | 3115.0 | Standard polar | 33892256 | Decitabine,3TMS,isomer #3 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C[C@@H]1O | 2324.5 | Semi standard non polar | 33892256 | Decitabine,3TMS,isomer #3 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C[C@@H]1O | 2492.6 | Standard non polar | 33892256 | Decitabine,3TMS,isomer #3 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C[C@@H]1O | 3137.0 | Standard polar | 33892256 | Decitabine,4TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C[C@@H]1O[Si](C)(C)C | 2336.5 | Semi standard non polar | 33892256 | Decitabine,4TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C[C@@H]1O[Si](C)(C)C | 2499.8 | Standard non polar | 33892256 | Decitabine,4TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C[C@@H]1O[Si](C)(C)C | 2890.6 | Standard polar | 33892256 | Decitabine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H](N2C=NC(N)=NC2=O)O[C@@H]1CO | 2555.0 | Semi standard non polar | 33892256 | Decitabine,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)C[C@@H]1O | 2551.4 | Semi standard non polar | 33892256 | Decitabine,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)C=N1 | 2578.3 | Semi standard non polar | 33892256 | Decitabine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 2706.7 | Semi standard non polar | 33892256 | Decitabine,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CO)O2)C=N1 | 2738.0 | Semi standard non polar | 33892256 | Decitabine,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O)[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C=N1 | 2736.9 | Semi standard non polar | 33892256 | Decitabine,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)N(C1=NC(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)C=N1)[Si](C)(C)C(C)(C)C | 2737.1 | Semi standard non polar | 33892256 | Decitabine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C=N1 | 2928.5 | Semi standard non polar | 33892256 | Decitabine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C=N1 | 3092.4 | Standard non polar | 33892256 | Decitabine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@H]2C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C=N1 | 3476.1 | Standard polar | 33892256 | Decitabine,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)O[C@@H]1CO | 2934.2 | Semi standard non polar | 33892256 | Decitabine,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)O[C@@H]1CO | 3106.6 | Standard non polar | 33892256 | Decitabine,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)O[C@@H]1CO | 3237.5 | Standard polar | 33892256 | Decitabine,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C[C@@H]1O | 2925.8 | Semi standard non polar | 33892256 | Decitabine,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C[C@@H]1O | 3123.2 | Standard non polar | 33892256 | Decitabine,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C[C@@H]1O | 3270.7 | Standard polar | 33892256 | Decitabine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 3135.1 | Semi standard non polar | 33892256 | Decitabine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 3325.1 | Standard non polar | 33892256 | Decitabine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 3181.0 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Decitabine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-9500000000-93e2d9110f2fded5b292 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Decitabine GC-MS (2 TMS) - 70eV, Positive | splash10-0gi0-6792000000-f27b73769db73752ebde | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Decitabine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 10V, Positive-QTOF | splash10-03di-0900000000-7976ff1b54184471f7f1 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 20V, Positive-QTOF | splash10-03di-5900000000-30985d6b34f33fc971bd | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 40V, Positive-QTOF | splash10-03dl-9600000000-7eb826f89c6a9e79fd1a | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 10V, Negative-QTOF | splash10-003r-4920000000-1d57eb49c2bfcee4a085 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 20V, Negative-QTOF | splash10-0006-9610000000-41445cf04cf3061ec547 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 40V, Negative-QTOF | splash10-014l-9200000000-49c5c1822d5d6ef31f04 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 10V, Positive-QTOF | splash10-03di-0900000000-ad27e26e064f360f3006 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 20V, Positive-QTOF | splash10-03di-4900000000-8baaf44cbb1e8b1eec0e | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 40V, Positive-QTOF | splash10-03di-7900000000-c1581650f477cf91f369 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 10V, Negative-QTOF | splash10-01ri-1940000000-983ffb62a26d8077f3b0 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 20V, Negative-QTOF | splash10-000x-8900000000-db8318379b860e59d087 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Decitabine 40V, Negative-QTOF | splash10-0006-9300000000-8f2a29e2dd6708ebd1ed | 2021-10-11 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum |
|
---|
General References | - Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Recent Results Cancer Res. 2010;184:131-57. doi: 10.1007/978-3-642-01222-8_10. [PubMed:20072836 ]
- Saba HI, Wijermans PW: Decitabine in myelodysplastic syndromes. Semin Hematol. 2005 Jul;42(3 Suppl 2):S23-31. [PubMed:16015501 ]
- Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun;112(11):2341-51. doi: 10.1002/cncr.23463. [PubMed:18398832 ]
- Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008 Jul 1;123(1):8-13. doi: 10.1002/ijc.23607. [PubMed:18425818 ]
- Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4. [PubMed:17023173 ]
- Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M: Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008 Apr;32(4):587-91. Epub 2007 Sep 18. [PubMed:17881052 ]
- Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007 Oct 10;25(29):4603-9. [PubMed:17925555 ]
|
---|